Bristol-Myers Squibb Company logo
Bristol-Myers Squibb Company (BMY)
Compare

BMY Balance Sheet

Assets, liabilities, and equity analysis

BMY Quarterly Balance Sheet (USD)

Quarterly ReportTTM
03/31/2026
12/31/2025
09/30/2025
06/30/2025
03/31/2025
12/31/2024
09/30/2024
06/30/2024
Total Current Assets
27.208B27.208B29.390B35.630B33.222B30.783B29.780B28.075B26.890B
9.574B9.574B10.209B15.726B12.599B10.875B10.346B7.890B6.293B
Short-Term Investments
912.000M912.000M464.000M776.000M1.004B907.000M513.000M204.000M360.000M
Cash & Short-Term Investments
10.486B10.486B10.673B16.502B13.603B11.782B10.859B8.094B6.653B
9.368B9.368B14.525B14.616B15.101B14.586B14.424B14.895B15.146B
2.756B2.756B2.690B2.758B2.737B2.666B2.557B3.332B3.077B
Total Assets
86.476B86.476B90.038B96.889B94.676B92.427B92.603B93.670B94.646B
7.658B7.658B9.125B7.349B8.649B8.428B8.360B8.251B8.161B
21.740B21.740B21.754B21.745B21.776B21.737B21.719B21.751B21.732B
Intangible Assets
18.244B18.244B19.353B20.465B21.663B22.802B23.643B27.327B29.839B
Long-Term Investments
0.000.002.507B2.358B2.252B2.250B2.508B2.853B2.999B
Total Current Liabilities
19.158B19.158B23.417B28.136B27.528B24.070B23.774B22.638B23.265B
4.234B4.234B3.575B4.288B5.427B4.002B3.602B3.469B3.751B
2.308B2.308B2.261B4.723B4.715B3.554B2.046B1.078B3.531B
Total Liabilities
66.374B66.374B71.532B78.289B77.187B74.979B76.215B76.470B77.577B
42.152B42.152B42.850B44.469B44.470B46.157B47.603B48.674B48.858B
44.460B44.460B47.139B51.041B50.929B51.239B51.200B51.400B54.004B
Net Debt (Cash)
34.886B34.886B36.930B35.315B38.330B40.364B40.854B43.510B47.711B
Total Shareholders' Equity
20.068B20.068B18.473B18.552B17.435B17.389B16.335B17.142B17.015B
Common Stock
292.000M292.000M292.000M292.000M292.000M292.000M292.000M292.000M292.000M
18.287B18.287B16.896B17.093B16.154B16.106B14.912B16.097B16.103B
1.421.421.261.271.211.281.251.241.16
2.222.222.552.752.922.953.133.003.17

BMY Annual Balance Sheet (USD)

Annual Report
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Total Current Assets
29.390B29.780B31.770B27.273B33.262B30.192B29.354B17.716B
10.209B10.346B11.464B9.123B13.979B14.546B12.346B6.911B
Short-Term Investments
464.000M513.000M816.000M130.000M3.242B1.904B3.047B1.848B
Cash & Short-Term Investments
10.673B10.859B12.280B9.253B17.221B16.450B15.393B8.759B
14.525B14.424B15.264B13.937B12.516B10.554B7.685B5.747B
2.690B2.557B2.662B2.339B2.095B2.074B4.293B1.195B
Total Assets
90.038B92.603B95.159B96.820B109.314B118.481B129.944B34.986B
9.125B8.360B8.036B7.475B6.968B6.745B6.956B5.027B
21.754B21.719B21.169B21.149B20.502B20.547B22.488B6.538B
Intangible Assets
19.103B23.643B27.485B36.355B42.775B53.449B63.969B1.091B
Long-Term Investments
2.507B2.508B2.499B2.187B2.713B4.509B4.172B1.775B
Total Current Liabilities
23.417B23.774B22.262B21.890B21.868B19.080B18.304B10.654B
3.575B3.602B3.259B3.040B2.949B2.713B2.445B1.892B
2.261B2.046B3.119B4.264B4.948B2.340B3.346B1.703B
Total Liabilities
71.532B76.215B65.674B65.702B73.308B80.599B78.246B20.859B
42.850B47.603B36.653B35.056B39.605B48.336B43.387B5.646B
47.139B51.200B41.464B40.717B45.596B51.673B47.538B7.349B
Net Debt (Cash)
36.930B40.854B30.000B31.594B31.617B37.127B35.192B438.000M
Total Shareholders' Equity
18.473B16.335B29.430B31.061B35.946B37.822B51.598B14.031B
Common Stock
292.000M292.000M292.000M292.000M292.000M292.000M292.000M221.000M
16.896B14.912B28.766B25.503B23.820B21.281B34.474B34.065B
1.261.251.431.251.521.581.601.66
2.553.131.411.311.271.370.920.52

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.

Princeton, NJ
34,100 employees
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Christopher S. Boerner